title: Ovarian cancer treatments on the horizon.
authors.forename: Charlie
authors.initials: C
authors.lastname: Schmidt
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy; D017277:Drug Approval / Q000379:methods; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D017063:Outcome Assessment, Health Care; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010793:Phthalazines / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D010793:Phthalazines; D010879:Piperazines; D000068258:Bevacizumab; C531550:olaparib